المؤلفون: Pepose JS, Hartman PJ, DuBiner HB, Abrams MA, Smyth-Medina RJ, Moroi SE, Meyer AR, Sooch MP, Jaber RM, Charizanis K, Klapman SA, Amin AT, Yousif JE, Lazar ES, Karpecki PM, Slonim CB, McDonald MB

المصدر: Clinical Ophthalmology, Vol Volume 15, Pp 79-91 (2021)

مصطلحات موضوعية: iop, presbyopia, night vision disturbances, dim light vision disturbances, pupil diameter, orion-1, Ophthalmology, RE1-994

وصف الملف: electronic resource

Relation: https://www.dovepress.com/phentolamine-mesylate-ophthalmic-solution-provides-lasting-pupil-modul-peer-reviewed-article-OPTH; https://doaj.org/toc/1177-5483

URL الوصول: https://doaj.org/article/6761b0dbbf40492bbcfb05ba44388bd5

المؤلفون: Karpecki PM; Kentucky College of Optometry, Pikeville, Kentucky., Foster SA; Athens Eye Care, Athens, Ohio., Montaquila SM; West Bay Eye Associates, Warwick, Rhode Island., Kannarr SR; Kannarr Eye Care, Pittsburg, Kansas., Slonim CB; Oculos Development Services, LLC, Tampa, Florida., Meyer AR; Ocuphire Pharma, Farmington Hills, Michigan., Sooch MP; Ocuphire Pharma, Farmington Hills, Michigan., Jaber RM; Ocuphire Pharma, Farmington Hills, Michigan., Charizanis K, Yousif JE; Ocuphire Pharma, Farmington Hills, Michigan., Klapman SA; Ocuphire Pharma, Farmington Hills, Michigan., Amin AT; Ocuphire Pharma, Farmington Hills, Michigan., McDonald MB; New York University Langone Medical Center, New York, New York., Horn GD; LasikPlus, Cincinnati, Ohio., Lazar ES; elCON Medical, Buffalo, New York., Pepose JS

المصدر: Optometry and vision science : official publication of the American Academy of Optometry [Optom Vis Sci] 2021 Mar 01; Vol. 98 (3), pp. 234-242.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 8904931 Publication Model: Print Cited Medium: Internet ISSN: 1538-9235 (Electronic) Linking ISSN: 10405488 NLM ISO Abbreviation: Optom Vis Sci Subsets: MEDLINE

مواضيع طبية MeSH: Adrenergic alpha-Antagonists/*pharmacology , Mydriatics/*administration & dosage , Phentolamine/*pharmacology , Pupil/*drug effects, Accommodation, Ocular/physiology ; Administration, Ophthalmic ; Adolescent ; Adult ; Cross-Over Studies ; Double-Blind Method ; Humans ; Male ; Ophthalmic Solutions ; Phenylephrine/administration & dosage ; Pupil Disorders ; Tropicamide/administration & dosage ; Young Adult

المؤلفون: Rodrigueza WV; ProNAi Therapeutics, Inc., Plymouth, MI, USA, wrodrigueza@pronai.com., Woolliscroft MJ, Ebrahim AS, Forgey R, McGovren PJ, Endert G, Wagner A, Holewa D, Aboukameel A, Gill RD, Bisgaier CL, Messmann RA, Whitehead CE, Izbicka E, Streeper R, Wick MC, Stiegler G, Stein CA, Monsma D, Webb C, Sooch MP, Panzner S, Mohammad R, Goodwin NC, Al-Katib A

المصدر: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2014 Jul; Vol. 74 (1), pp. 151-66. Date of Electronic Publication: 2014 May 16.

نوع المنشور: Comparative Study; Journal Article

بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*therapeutic use , DNA, Antisense/*therapeutic use , DNA, Single-Stranded/*therapeutic use , Gene Silencing/*drug effects , Neoplasms/*drug therapy , Proto-Oncogene Proteins c-bcl-2/*antagonists & inhibitors, 5' Flanking Region/drug effects ; Animals ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/pharmacokinetics ; Antineoplastic Agents/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/metabolism ; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cell Line, Tumor ; Cell Survival/drug effects ; DNA, Antisense/administration & dosage ; DNA, Antisense/pharmacokinetics ; DNA, Antisense/pharmacology ; DNA, Single-Stranded/administration & dosage ; DNA, Single-Stranded/pharmacokinetics ; DNA, Single-Stranded/pharmacology ; Drug Compounding ; Drug Stability ; Female ; Liposomes ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Mice, SCID ; Neoplasms/blood ; Oligodeoxyribonucleotides/chemistry ; Oligodeoxyribonucleotides/pharmacokinetics ; Oligodeoxyribonucleotides/pharmacology ; Oligodeoxyribonucleotides/therapeutic use ; Pharmaceutical Vehicles ; Proto-Oncogene Proteins c-bcl-2/genetics ; Proto-Oncogene Proteins c-bcl-2/metabolism ; Random Allocation ; Xenograft Model Antitumor Assays

المؤلفون: Tolcher AW; South Texas Accelerated Research Therapeutics (START), LLC, San Antonio, TX, USA., Rodrigueza WV, Rasco DW, Patnaik A, Papadopoulos KP, Amaya A, Moore TD, Gaylor SK, Bisgaier CL, Sooch MP, Woolliscroft MJ, Messmann RA

المصدر: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2014 Feb; Vol. 73 (2), pp. 363-71. Date of Electronic Publication: 2013 Dec 03.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Neoplasms/*drug therapy , Oligodeoxyribonucleotides/*administration & dosage , Oligonucleotides/*administration & dosage , Proto-Oncogene Proteins c-bcl-2/*genetics, Adult ; Aged ; Aged, 80 and over ; DNA/antagonists & inhibitors ; Female ; Humans ; Liposomes/administration & dosage ; Male ; Maximum Tolerated Dose ; Middle Aged ; Molecular Targeted Therapy ; Neoplasms/genetics ; Neoplasms/metabolism ; Neoplasms/pathology ; Oligonucleotides/adverse effects ; Oligonucleotides/pharmacokinetics ; Treatment Outcome